ClinicalTrials HQ

Shanghai Junshi Bioscience Co., Ltd.

Shanghai Junshi Bioscience Co., Ltd.

Explore linked clinical trials.

42 results · Page 1 of 2

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver CancerDigestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasmNot yet recruitingPhase 32026-09-16NCT07823348
Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLCNeoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmNot yet recruitingPhase 22026-09-15NCT07819578
A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaB-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasmNot yet recruitingPhase 32026-09-09NCT07808827
JS203 Combination Regimens in B-Cell Non-Hodgkin's LymphomaB-cell neoplasm, B-cell non-Hodgkin lymphoma, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasmActive, not recruitingPhase 22026-09-04NCT07081022
Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical ResectionDigestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasmActive, not recruitingPhase 2 / Phase 32026-08-10NCT03859128
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid TumorsAdvanced Solid TumorsActive, not recruitingPhase 12026-08-07NCT05502393
JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLCNeoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmActive, not recruitingPhase 22026-08-04NCT06969027
JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLCnon-small cell lung carcinomaActive, not recruitingPhase 22026-07-27NCT06944470
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinomaRecruitingPhase 32026-07-27NCT06095583
A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid TumourAdvanced Malignant Solid TumoursRecruitingPhase 1 / Phase 22026-07-08NCT06888830
JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II StudyNeoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmRecruitingPhase 22026-07-07NCT07518160
Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II TrialDigestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorderRecruitingPhase 22026-07-07NCT07106034
Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid TumorsAdvanced Malignant Solid TumorsActive, not recruitingPhase 12026-07-07NCT06571422
PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerGastric or Esophagogastric Junction AdenocarcinomaActive, not recruitingPhase 32026-07-07NCT05180734
Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCCAdvanced Hepatocellular Carcinoma (HCC)Active, not recruitingPhase 32026-07-06NCT04523493
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced MalignanciesDigestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, intestinal disorder, kidney cancer, kidney disorder, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, rectal disorder, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, urinary system disorderRecruitingPhase 12026-07-02NCT06839105
The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant TumorAdvanced Malignant TumorActive, not recruitingPhase 12026-07-02NCT06022250
Selective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cancer (SCIENCE Study)Selective Mediastinal Lymph Node Sampling; Stage IIA-IIIB NSCLC; Systematic medIastinal Lymph Node DissectionNot yet recruitingPhase 32026-06-01NCT07617389
Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid TumorsAdvanced Malignant Solid TumorsRecruitingPhase 22026-05-29NCT07480733
A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung CancerAdvanced Lung CancerRecruitingPhase 22026-05-18NCT07309276
Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI TherapyNon-squamous Non-small Cell Lung CancerRecruitingPhase 22026-05-18NCT06868836
JS212 Combination Therapies in Metastatic Colorectal CancerDigestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorderRecruitingPhase 22026-05-05NCT07503756
A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell CarcinomaAdvanced Esophageal Squamous Cell CarcinomaRecruitingPhase 22026-04-22NCT07484724
JS207 Combination Therapy in Triple-negative Breast CancerNeoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinomaRecruitingPhase 22026-04-15NCT07045311
Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaResectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingPhase 32026-04-08NCT04848753